{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T13:43:03Z","timestamp":1777902183166,"version":"3.51.4"},"reference-count":3,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2000,12,1]],"date-time":"2000-12-01T00:00:00Z","timestamp":975628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Scott Med J"],"published-print":{"date-parts":[[2000,12]]},"abstract":"<jats:p>Affective (mood) disorders are common in all ages often chronic or recurrent, destructive of personal and social functioning with significant morbidity and mortality. Diagnosis still rests on the clinical skills of interview, observation and a knowledge of the disorders. Lithium is simple, cheap and effective although underused. It is the main pharmacological agent currently used in bipolar disorders and as an adjunct in other affective disorders. While it does have a narrow therapeutic window and can cause serious morbidity itsxelf, it is safe when delivered properly reducing both morbidity and mortality. Lithium therapy should only be started in a specialist psychiatric setting but other clinicians will be involved either in maintenance treatment or in treating patients for separate disorders who happen also to be on lithium.<\/jats:p>","DOI":"10.1177\/003693300004500604","type":"journal-article","created":{"date-parts":[[2017,1,7]],"date-time":"2017-01-07T01:20:04Z","timestamp":1483752004000},"page":"171-173","source":"Crossref","is-referenced-by-count":3,"title":["Lithium Therapy"],"prefix":"10.1177","volume":"45","author":[{"given":"G.","family":"Dodds","sequence":"first","affiliation":[{"name":"Department of Psychiatric Medicine, Falkirk Royal Infirmary, Falkirk."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2000,12,1]]},"reference":[{"key":"bibr1-003693300004500604","unstructured":"Mood(Affective) Disorders, F30-39 ICD-10 Classification of mental and behavioural disorders. World Health Organisation 1992; Geneva, Version 10: 110\u2013131."},{"key":"bibr2-003693300004500604","unstructured":"Whitby LG, Smith AF, Becket GJ, Walker SW. Renal disease. Lecture notes on Clinical Biochemistry. Blackwell Sciennce, Oxford 1993; 5th edition p 126."},{"key":"bibr3-003693300004500604","unstructured":"Appendix 1. British National Formulary, London BMA\/Royal Pharmaceutical Society 1999; Vol 27: 585."}],"container-title":["Scottish Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/003693300004500604","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/003693300004500604","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T11:22:14Z","timestamp":1777634534000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/003693300004500604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,12]]},"references-count":3,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2000,12]]}},"alternative-id":["10.1177\/003693300004500604"],"URL":"https:\/\/doi.org\/10.1177\/003693300004500604","relation":{},"ISSN":["0036-9330","2045-6441"],"issn-type":[{"value":"0036-9330","type":"print"},{"value":"2045-6441","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,12]]}}}